Amylyx Pharmaceuticals, Inc. $AMLX Shares Sold by Walleye Capital LLC

Key Points

• Walleye Capital LLC has reduced its stake in Amylyx Pharmaceuticals by 50.6%, now holding 250,888 shares after selling over 257,000 shares in the first quarter.
• Goldman Sachs upgraded Amylyx Pharmaceuticals to a "buy" rating, setting a price target of $10.00, while Citigroup also issued a buy rating with a price target of $12.00.
• Amylyx Pharmaceuticals' stock is currently trading at $9.38 with a market capitalization of approximately $836.41 million and a one-year high of $9.72.

Walleye Capital LLC lowered its holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 50.6% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 250,888 shares of the company's stock after selling 257,396 shares during the period. Walleye Capital LLC owned approximately 0.28% of Amylyx Pharmaceuticals worth $888,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the business. Bank of America Corp DE grew its holdings in Amylyx Pharmaceuticals by 165.9% during the 4th quarter. Bank of America Corp DE now owns 2,426,263 shares of the company's stock worth $9,171,000 after acquiring an additional 1,513,748 shares in the last quarter. Aberdeen Group plc lifted its position in shares of Amylyx Pharmaceuticals by 41.1% during the 1st quarter. Aberdeen Group plc now owns 2,430,358 shares of the company's stock worth $8,603,000 after buying an additional 707,553 shares during the last quarter. Cubist Systematic Strategies LLC lifted its position in shares of Amylyx Pharmaceuticals by 862.5% during the 4th quarter. Cubist Systematic Strategies LLC now owns 472,397 shares of the company's stock worth $1,786,000 after buying an additional 423,316 shares during the last quarter. Jane Street Group LLC lifted its position in shares of Amylyx Pharmaceuticals by 122.4% during the 4th quarter. Jane Street Group LLC now owns 765,475 shares of the company's stock worth $2,893,000 after buying an additional 421,302 shares during the last quarter. Finally, Orbimed Advisors LLC purchased a new stake in Amylyx Pharmaceuticals in the 4th quarter valued at $1,315,000. Institutional investors and hedge funds own 95.84% of the company's stock.

Analysts Set New Price Targets

Several analysts recently commented on AMLX shares. HC Wainwright upped their price target on shares of Amylyx Pharmaceuticals from $12.00 to $16.00 and gave the company a "buy" rating in a research report on Friday, May 9th. Wall Street Zen upgraded shares of Amylyx Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Friday, July 18th. The Goldman Sachs Group upgraded shares of Amylyx Pharmaceuticals to a "buy" rating and set a $10.00 price objective for the company in a research report on Thursday, July 10th. Bank of America upped their price objective on shares of Amylyx Pharmaceuticals from $10.00 to $14.00 and gave the stock a "buy" rating in a research report on Thursday, August 28th. Finally, TD Cowen began coverage on shares of Amylyx Pharmaceuticals in a research report on Friday, May 30th. They set a "buy" rating for the company. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, Amylyx Pharmaceuticals presently has a consensus rating of "Buy" and an average price target of $12.25.

Amylyx Pharmaceuticals Trading Up 0.0%

Shares of NASDAQ:AMLX traded up $0.00 on Friday, reaching $9.95. 389,322 shares of the company were exchanged, compared to its average volume of 1,131,868. Amylyx Pharmaceuticals, Inc. has a 1-year low of $2.28 and a 1-year high of $10.19. The firm has a market cap of $887.51 million, a price-to-earnings ratio of -3.99 and a beta of -0.44. The company has a 50-day moving average of $8.07 and a 200-day moving average of $5.65.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.02). As a group, analysts forecast that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current year.

Amylyx Pharmaceuticals Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.